Congestive heart failure remains a complex pathophysiologic syndrome associated with
significant morbidity and mortality. Although advances in therapy, particularly with …

The efficacy of beta-blocking drugs in the treatment of chronic heart failure remains
controversial. A major obstacle to their acceptance in this pharmacotherapeutic role has …

The use of β-blocker therapy in heart failure was contraindicated for many years because it
was considered to block necessary sympathetic compensatory responses to reduced …

Airmail rates available on request.* Canadian 7% Goods and Services Tax, calculated on
US base rate, has been added and will be paid to Revenue Canada under GST No …

The use of a b-blocker for the treatment of heart failure was for a long time contraindicated.
The reasons were mainly due to concerns that the failing circulatory system needed …

ContextCare of patients with heart failure has been revolutionized throughout the past
decade. A paradigm shift in the strategy for treating heart failure caused by systolic …

Despite advances in knowledge and treatment, heart failure remains a serious and common
health problem in the Western world. There are an estimated 4á8 million Americans …

Although recent advances have been made in the treatment of heart failure, this disease
continues to result in significant morbidity and mortality. Among the negative effects …

Heart failure is an important public health problem and one for which morbidity and mortality
remain high despite treatment with angiotensin converting enzyme (ACE) inhibitors. A large …

OBJECTIVE: To briefly discuss the pathophysiology of heart failure and the rationale for the
use of β-blockers in the treatment of chronic heart failure. Key morbidity reduction trials are …